By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Novavax (NASDAQ:NVAX) shares climbed about 5% on Tuesday after the biotech group disclosed a non-exclusive licensing ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...

Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M ...

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.